Before you formulate with PDRN, get three things straight. The cosmetic-grade material is not the same substance as the injectable one. The evidence that supports clinical use does not transfer automatically to a topical product. And the claim line sits lower than most marketing teams expect. PDRN — polydeoxyribonucleotide, listed on ingredient labels as Sodium DNA — has moved quickly out of aesthetic clinics and into serums and ampoules, and the sourcing and compliance questions have travelled with it. This piece covers the formulation and regulatory side of that decision; the supplier-qualification side is set out separately in our guide to sourcing PDRN without crossing claim lines.
What Is PDRN, and Where Does Cosmetic-Grade Material Come From?
PDRN is a polymer made up of DNA fragments. Reported molecular weights span a wide band, roughly 50 to 1500 kDa, while cosmetic-grade material typically sits in the 80 to 200 kDa range. That spread matters more than it looks: fragment length, purity and molecular weight distribution all shape how the ingredient behaves in a formula and how much of it you can justify on a label.
On the INCI list it appears as Sodium DNA. Depending on the supplier and the market, you may also see Polydeoxyribonucleotide or Salmon DNA on packaging copy, so check which name your regulatory partner expects in each jurisdiction.
The traditional source is salmonid milt — salmon or trout — put through multi-stage purification. Two further routes are now commercial: microbial fermentation, and synthetic biology routes that design the base sequence directly. They matter for two reasons: they remove the animal-origin question from vegan positioning, and they give far tighter control over fragment length.
One practical trap worth flagging. Suppliers do not agree on a CAS number for this material; the same ingredient appears under several different numbers across specification sheets. Rather than picking one, ask for the number on the supplier’s own COA and resolve any mismatch against your regulatory documentation before purchase, not after.
How Is PDRN Thought to Work, and How Strong Is the Evidence?
Two mechanisms are usually described. The first runs through the A2A adenosine receptor: breakdown products bind to the receptor, raising intracellular cAMP and, in laboratory work, supporting fibroblast activity, VEGF expression and collagen I and III synthesis. The second is the nucleotide salvage pathway, where the fragments supply purine and pyrimidine precursors that cells can draw on for nucleotide synthesis.
Here is where brands need to slow down. Most of that mechanistic and clinical work was done in an injectable or clinical research context, and a good deal of the rest is in vitro. Evidence generated at injectable concentrations and delivery depths does not automatically describe what a leave-on serum does. The industry is still short of large, long-term human studies on topical PDRN at cosmetic concentrations.
Size is the physical reason. PDRN molecules sit far above the range that crosses an intact stratum corneum with any ease. A topical product works largely at the epidermal level; an injectable delivers material into the dermis. Same active, different depth, different evidence base.
Two persistent misconceptions deserve a direct answer. Topical PDRN does not integrate into your skin cells’ own DNA, and it is not a gene-level technology. It is a cosmetic ingredient that acts through cell-surface receptors and nucleotide supply. Marketing that drifts toward gene-level language crosses out of cosmetics entirely.
Where Does Topical PDRN Sit in the EU, US, and China?
The short answer in all three markets: topical is a cosmetic, injectable is not.
European Union. PDRN is not listed in Annexes II to VI of Regulation (EC) No 1223/2009, which means it is neither prohibited nor restricted by name. CosIng records it as a skin conditioning agent. Products containing it need CPNP notification before market placement (SCPN in the UK), and because the material is biologically derived, the CPSR should assess it case by case — source traceability, purity, residual protein and molecular weight distribution all belong in that assessment. Note the contrast on the other side of the line: injectable polynucleotide products are Class III medical devices under the MDR, requiring notified body review and a clinical evaluation.
United States. A topical PDRN product goes down the cosmetic route with no pre-market approval, but MoCRA obligations still apply — facility registration, product listing, and substantiated safety data behind the formula. On the injectable side, no PDRN product has been approved by the FDA for aesthetic indications, and anything positioned as having a corrective effect would be looked at as a drug or biologic.
China. DNA钠 is included in the Inventory of Existing Cosmetic Ingredients in China (2021 edition) under entry 00383, so topical products follow the standard cosmetic filing path. The injectable route differs: NMPA classification results have defined injectable PDRN combination solutions, and injectable polynucleotide gel, as drug-device combination products. As of early 2025 no domestically approved Class III PDRN device had reached the market, though more than ten companies had completed master file registration.
South Korea, the most mature market for injectable PDRN, classifies those products as Class III medical devices under MFDS.
What Concentration and Processing Window Should You Work In?
Concentration tiers circulating in the industry look roughly like this: 0.05–0.1% for basic hydration and concept-level dosing, 0.1–0.5% for regular conditioning and soothing, and 0.5–2% for premium anti-ageing positioning. Published reference figures for leave-on products on the Chinese market run higher — around 2.5% for body and 3.67% for face — but read these as industry practice rather than legal ceilings, and confirm the window against your supplier’s specification sheet.
Processing is where good intentions get lost. PDRN is water-soluble, holds up well in a mildly acidic to neutral pH window, and is heat sensitive, so it belongs in the cool-down phase rather than the hot side of the batch. Compatibility is generally good with hyaluronic acid, niacinamide, vitamins C and E, and ceramides. Low-pH systems built around AHAs or BHA need their own verification. As with any biologically derived material, run a full preservation system and watch the incoming bioburden of the raw material.
One more caution: more is not automatically better. In vitro work on cell proliferation does not show a straight line between dose and response, so resist treating concentration as the headline number on the packaging.
Where Exactly Are the Claim Lines?
Three variables decide where a product lands: dosage form, intended use, and how the mechanism is described. Get any one wrong and a cosmetic starts looking like a drug or a device to a regulator.
Comfortable cosmetic territory includes skin conditioning, hydration, soothing, improving the look and feel of skin, and supporting barrier function — for example, "helps skin look smoother" or "supports the skin’s moisture barrier."
What sits outside it: tissue-level repair or regeneration as a performance claim, collagen regeneration positioned as a product benefit, clinical-grade positioning that implies device or drug status, anything framed at the gene level, and any suggestion of a corrective effect. The "medical aesthetics-inspired" styling that borrowed PDRN’s credibility in the first place is precisely what pulls a topical product toward the wrong classification.
Two more that catch brands out. Animal-derived PDRN is not a vegan ingredient, so a vegan claim needs a documented recombinant or plant-source route behind it. And while purification is designed to remove protein, controlled human studies covering every processing grade are not there — for a formula aimed at reactive skin, a recombinant source is the more conservative choice.
What Should You Demand From a Supplier?
Commercial PDRN is not a uniform commodity. Fragment length, purity grade, molecular weight distribution and measured bioactivity all vary between producers, and two materials carrying the same INCI name can behave very differently. Neither CIR nor SCCS has issued an assessment specific to Sodium DNA or PDRN, though CIR has assessed the broader DNA category as safe under current cosmetic use practices.
Concept dosing is a real problem here, and it is difficult to spot from the label. Ask for the COA with the test method stated, the full specification sheet, SDS/MSDS, stability and compatibility data, origin and traceability documents — including a BSE/TSE-free statement for animal-derived material — plus microbial and heavy metal results and an independent third-party retest. If you are filing in China, get written confirmation that the material is the IECIC-listed DNA钠 under entry 00383.
Building a PDRN Line With a Manufacturing Partner
PDRN rewards preparation. The brands that move quickly are the ones who settle the specification, the claim set and the documentation package with their manufacturing partner before the first trial batch, rather than discovering a gap at the filing stage.
CHONGSHENG FUTURE (重生未来) works with brands on exactly that sequence — ingredient and supplier review, formula development within a defined concentration and pH window, stability and compatibility work, and a claim set aligned to the market you are selling in. If you are weighing a PDRN serum, ampoule or essence, send over your target market, product format and positioning, and we will tell you what is realistic before you commit to a batch.